Compare MLSS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLSS | BCTX |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 36.6M |
| IPO Year | 1996 | 2025 |
| Metric | MLSS | BCTX |
|---|---|---|
| Price | $0.30 | $3.44 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.25 | N/A |
| AVG Volume (30 Days) | 82.4K | ★ 84.8K |
| Earning Date | 08-13-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,973,982.00 | N/A |
| Revenue This Year | $11.14 | N/A |
| Revenue Next Year | $13.80 | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $2.60 |
| 52 Week High | $0.58 | $13.90 |
| Indicator | MLSS | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.46 | 38.37 |
| Support Level | $0.24 | $3.35 |
| Resistance Level | $0.31 | $3.74 |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 5.71 | 9.08 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.